| Connect Hearing, Inc. | |
|
1940 W Orangewood Ave Ste 110, Orange, CA 92868-5042 | |
| (714) 978-2996 | |
| (714) 978-2824 |
| Full Name | Connect Hearing, Inc. |
|---|---|
| Type | Facility |
| Speciality | Hearing Aid Equipment |
| Location | 1940 W Orangewood Ave Ste 110, Orange, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215289228 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Connect Hearing, Inc. 750 N Commons Dr Ste 200, Aurora, IL 60504-7940 Ph: (630) 303-5380 | Connect Hearing, Inc. 1940 W Orangewood Ave Ste 110, Orange, CA 92868-5042 Ph: (714) 978-2996 |
News Archive
Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan (rifaximin) 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. Those HE patients may now fill their Xifaxan 550 mg prescriptions in U.S. pharmacies and should speak with their doctors about this important treatment option.
The Catalysis Foundation for Health (Catalysis), a 501 (c) (3) non-profit entity dedicated to developing sustainable diagnostics for the developing world, announced today that it has received a $5 million grant from the Bill & Melinda Gates Foundation. The grant money will be used to discover new tuberculosis (TB) biomarkers that can be used to improve diagnostic tests and potentially develop more effective TB treatments.
Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to late-breaking results from the COMPASS trial presented today in a Hot Line - LBCT Session at ESC Congress1 and published in the NEJM.
Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment of the first patient in a Phase 2 study with CXA-201. This multicenter, double-blind, randomized, study will compare the safety and efficacy of intravenous CXA-201 with an active comparator in patients with complicated intra-abdominal Infections (cIAI). This international study is expected to enroll 120 patients.
It's no secret that low-birth-weight babies face significantly greater risks for certain health problems early on, such as respiratory distress or infection. Now, a new study from researchers at the University of Florida and Northwestern University shows that lower weights at birth also have an adverse effect on children's performance in school, which is likely due to the early health struggles small babies often face.
› Verified 4 days ago